XAIR — Beyond Air, Inc.

Nasdaq · Health Care · Health Care Equipment & Supplies · CIK 1641631 ·
Last close
$0.42
Market Cap
$6.01M
52W High
$0.72
52W Low
$0.34
ADV30
263,140
Next earnings
2026-08-11
Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company. It operates through Beyond Air, Beyond Cancer, and NeuroNos segments. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO to treat viral lung infections, such as viral community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria (NTM). In addition, the company develops ultra-high concentration NO (UNO) that is in Phase 1 clinical trial to treat solid tumors; and selective neuronal nitric oxide synthase (nNOS) inhibitor for the treatment of neurological conditions. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 1,907,000 94,000 -7,170,000 -10,282,000 35,385,000 6,740,000 29,175,000
Dec 2025 2,194,000 300,000 -6,596,000 -7,336,000 36,774,000 6,643,000 28,488,000
Sep 2025 1,818,000 -298,000 -7,661,000 -7,940,000 30,965,000 9,699,000 17,870,000
Jun 2025 1,760,000 156,000 -7,617,000 -7,691,000 28,114,000 4,976,000 17,706,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-20,155,000
Investing CF
$-646,000
Financing CF
$28,689,000
CapEx
$-1,976,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-5.43
As of
2026-06-28

Balance + Analyst (yfinance extras)

Retained Earnings
$-309,289,000
Inventory
$1,761,000
Receivables
$1,259,000
ST Investments
$5,018,000
EBIT TTM
$-29,174,000
Pretax Income TTM
$-32,029,000
Interest Exp TTM
$2,855,000
Analysts
2

Yahoo Snapshot (yfinance, live)

Total Revenue
$7,679,000
EBITDA
$-25,793,000
Free Cash Flow
$-14,123,375
Enterprise Value
$17,987,540
Total Cash
$11,641,000
Total Debt
$23,384,000
Shares Out
14,410,621
Trailing EPS
$-4.01
Book Value
$0.96
ROE
-334.1%
ROA
-55.5%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Mar 2026 7,679,000 -29,044,000 -33,249,000 35,385,000 29,175,000 -18,144,000
Mar 2025 3,705,000 -44,537,000 -46,625,000 30,062,000 15,721,000 -38,218,000
Mar 2024 1,159,000 -63,007,000 -60,242,000 56,961,000 29,775,000 -56,014,000
Mar 2023 0 -52,059,000 -55,816,000 68,749,000 26,721,000 -33,009,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-1.66

Peers — same industry

TickerNameMarket CapLastDaily %
VVOS Vivos Therapeutics, Inc. $6.00M $0.43
SNOA Sonoma Pharmaceuticals, Inc. $6.03M $1.26
STME Stimcell Energetics Inc. $5.83M $0.28
MHUAF Meihua International Medical Technologies Co., Ltd. $5.74M $6.71
WOK WORK Medical Technology Group LTD $5.56M $2.30

News headlines (Yahoo Finance, 1h cache)

Beyond Air (XAIR) Q4 2026 Earnings Call Transcript
2026-06-27 00:31 · Yahoo
Beyond Air Inc (XAIR) Q4 2026 Earnings Call Highlights: Revenue Surge and Path to Profitability
2026-06-26 19:00 · Yahoo
Beyond Air® Reports Fourth Quarter and Full Year 2026 Financial Results and Provides Corporate Update
2026-06-26 11:00 · Yahoo
Beyond Air Schedules Fiscal Year End 2026 Financial Results Conference Call and Webcast
2026-06-22 20:01 · Yahoo
Beyond Air, Inc. Urges Stockholders to Vote “FOR” All Proposals Ahead of the Upcoming Special Meeting
2026-06-10 12:00 · Yahoo
Beyond Air Receives Nasdaq Hearing Panel Decision Granting Continued Listing
2026-06-01 12:00 · Yahoo
Beyond Cancer Reports Updated Survival and Safety Data from Phase 1 UNO Trial Presented at AACR 2026
2026-04-20 12:00 · Yahoo
Beyond Air to Participate in the D. Boral Capital Global Conference 2026
2026-04-15 12:00 · Yahoo
Beyond Air Expands Commercial Access for LungFit® PH Through a Purchasing Agreement with a Top 3 National Group Purchasing Organization (GPO)
2026-04-01 13:00 · Yahoo
Beyond Air, Inc. Announces Resignation of Steve Lisi, CEO, and Appointment of Robert Goodman, Chief Commercial Officer, as CEO
2026-03-26 20:05 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.